Hantavirus pulmonary syndrome (HPS) is a severe respiratory disease. Building on our groundbreaking work in HPS research, we lead the way in creating state-of-the-art diagnostic solutions to improve the efficient management of HPS. Serving as your reliable ally in HPS diagnostic research, we offer unmatched assistance to address your research requirements.
Introduction to Hantavirus Pulmonary Syndrome
Hantavirus pulmonary syndrome (HPS) is a rare but severe respiratory disease caused by various hantaviruses primarily carried by rodents such as mice and rats. The virus is transmitted to humans through contact with infected rodent feces, urine, or saliva. Upon infection, HPS can lead to rapid and life-threatening respiratory failure, making early diagnosis crucial for effective intervention and therapeutics.
Fig. 1 Immune mechanisms involvement in hantavirus prognosis disease. (Saavedra F, et al., 2021)
Diagnostic Biomarkers for Hantavirus Pulmonary Syndrome
Hantavirus pulmonary syndrome (HPS) presents several challenges in diagnosis, including its nonspecific early symptoms that can mimic other respiratory illnesses. The identification of specific biomarkers is crucial for early diagnosis, therapeutic initiation, and disease progression monitoring.
N Protein and Glycoprotein
Antigenic biomarkers are viral proteins or components that serve as evidence of active infection. The N protein is crucial for virus RNA packaging, while the glycoproteins Gn and Gc are responsible for virus entry into host cells. These proteins can serve as potential antigen targets for diagnostic assays of HPS.
IgM and IgG Antibodies
Antibody biomarkers are produced by the host immune system in response to Hantavirus infection and can be detected in serum samples. The presence of IgM antibodies indicates recent infection, while the presence of IgG antibodies indicates past exposure to the virus or current infection.
Viral RNA
Nucleic acid testing involves the use of molecular techniques such as PCR to detect the viral genetic material, such as RNA. RT-qPCR is used to detect and quantify Hantavirus RNA in samples, providing information about viral load and aiding in the diagnosis and monitoring of HPS.
IVD Development for Hantavirus Pulmonary Syndrome
Based on the diagnostic biomarkers of Hantavirus pulmonary syndrome (HPS), the development of corresponding in vitro diagnostic (IVD) kits is crucial to enhance diagnostic capabilities, improve therapeutic outcomes, and prevent the spread of HPS. The development of IVD kits relies on advanced detection technologies such as ELISA and immunoassays, PCR, and point-of-care testing methods. The following outlines the directions for HPS IVD kit development.
ELISA and Immunoassay Kits
The development of ELISA and immunoassay kits for HPS revolves around identifying unique viral antigens or host immune response markers crucial for accurate diagnosis. These kits are designed to detect Hantavirus antigens or antibodies in samples with high sensitivity and specificity.
PCR Test Kits
Polymerase chain reaction (PCR) test kits play a pivotal role in detecting Hantavirus nucleic acids, offering a molecular-level approach to diagnosis. These kits amplify and detect viral genetic material in samples, aiding in early and accurate identification of HPS infections.
Point-of-Care Test Kits
Point-of-care test kits rapid and on-the-spot diagnosis, proving invaluable in resource-limited settings and during outbreaks. These portable and convenient kits offer quick and qualitative detection of Hantavirus infection, enabling immediate decision-making and disease management.
Our Services
Specializing in delivering cutting-edge in vitro diagnostic (IVD) solutions for rare infectious diseases like Hantavirus pulmonary syndrome (HPS), our company is dedicated to developing tailor-made antigen, antibody, microbial, and nucleic acid detection kits to enhance early detection and efficient control of HPS. These kits are utilized alongside auxiliary diagnostic devices to maximize detection sensitivity and specificity.
IVD Product Development Services
Recognizing the importance of point-of-care testing (POCT) in resource-limited settings, our scientists excel in developing rapid diagnostic tests for on-site Hantavirus pulmonary syndrome (HPS) detection. Our companion diagnostic development service focuses on integrating diagnostic tests with specific therapies to achieve personalized therapeutics for HPS management.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Saavedra F, Díaz F E, Retamal‐Díaz A, et al. Immune response during hantavirus diseases: implications for immunotherapies and vaccine design[J]. Immunology, 2021, 163(3): 262-277.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
